Daily Brief Highlights

The Corner Skin Specialist Clinic Introduces Winlevi for Acne — The clinic has partnered with Hyphens Pharma to launch Winlevi, the first topical androgen receptor inhibitor designed to treat acne at its hormonal root without systemic side effects. Rise in Shingles Cases Prompts Vaccination Calls in Sarawak — Specialists in Kuching are reporting a surge in shingles cases and advocating for the Shingrix vaccine, a two-dose regimen with over 90 percent efficacy for adults aged 50 and above.

Introduction of Winlevi Topical Acne Treatment — Corner Skin Specialist Clinic and Hyphens Pharma have introduced Winlevi, the first topical androgen receptor inhibitor designed to treat acne at the hormonal root without systemic side effects. Upcoming Professional Medical Conferences and Masterclasses — Major industry events including ADAMS 2026, the Sarawak Plastic Surgery Update, and the first Primary Care Dermatology Conference are now open for registration and practitioner...

National Launch of Winlevi for Acne Treatment — The Corner Skin Specialist Centre has been selected as the trial site for Winlevi, the first topical androgen receptor inhibitor designed to treat acne without systemic hormonal side effects. Emergence of Shingrix as Preferred Shingles Vaccine — Dermatologists are recommending the Shingrix vaccine for adults over 50 and immunocompromised individuals, citing over 90 percent effectiveness in preventing shingles and post-herpetic neuralgia.

First Topical Acne Hormonal Blocker Winlevi Debuts in Malaysia — Corner Skin Specialist Centre has been named the Sarawak trial center for Winlevi, the first topical androgen receptor inhibitor that treats acne at the hormonal root without systemic side effects. Malaysia to Host Major Dermatology and Aesthetic Medicine Conferences — Key upcoming events include the Primary Care Dermatology Conference in August 2026 and ADAMS 2026 in July, focusing on clinical excellence and industry safety...

Winlevi Introduced as First Topical Androgen Receptor Inhibitor for Acne — Winlevi (clascoterone 1% cream) has been launched as the world's first topical androgen receptor inhibitor for acne, targeting hormonal causes without systemic side effects. Approved for use in patients aged 12 and above, it blocks DHT to reduce sebum overproduction and is clinically proven for both men and women. Shingrix Vaccine Recommended for Shingles Prevention in Adults — The Shingrix vaccine is now...

Shingrix vaccine recommended for adults 50+ to prevent shingles — The Shingrix vaccine is highlighted as a highly effective defense against shingles, with over 90% efficacy for adults aged 50 and above, including those who have previously had shingles. The virus, which causes shingles, affects 1 in 3 people and can lead to severe, long-lasting pain. Promotions launched for skin rejuvenation and anti-aging treatments — Clinics are offering limited-time deals on treatments like Rejuran...

Dermatology conference highlights latest clinical innovations — The Borneo Dermatology Update 2026 featured expert lectures on conditions like lichen sclerosus, acne treatments, and facial dyspigmentation. Presentations emphasized evidence-based approaches for Asian skin and emerging therapies such as topical anti-androgens for hormonal acne. Biologics show promise in treating autoimmune blistering disorders — Omalizumab, an anti-IgE biologic, is demonstrating effectiveness in treating...

Neoasia Clinical Forum 2026 to showcase dermatological innovations — Neoasia will host its Clinical Forum 2026 in Singapore on 28 April, featuring advancements such as Accure’s targeted acne laser technology and Heliocare’s ASPA-Fernblock technology for UV protection and Vitamin D receptor preservation. Leading experts will present clinical insights. Neoasia Vietnam Profhilo Awards 2026 celebrates aesthetic excellence — Neoasia Vietnam will host the Profhilo Awards 2026 on 21 April under...